Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 533 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Particle Clear all
Recruiting No phase listed Observational

SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism

NCT03222375
View directory record Official record
Conditions
Autistic Disorder, Autism Spectrum Disorder, Child Development Disorders, Pervasive, Neurodevelopmental Disorders, Mental Disorders, Asperger's Syndrome, Neurobehavioral Manifestations, Nervous System Diseases
Interventions
SQUED™ series 28.1 home-use
Device
Lead sponsor
American Federation of Medical Synergetics
Other
Eligibility
1 Month to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 23, 2026, 4:19 AM EDT
Terminated Phase 1 Interventional

First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

NCT04761601
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
UCT-01-097, Gemcitabine, Paclitaxel
Drug
Lead sponsor
1200 Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Los Angeles, California • Torrance, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 23, 2026, 4:19 AM EDT
Active, not recruiting Not applicable Interventional

Elbow Artery Embolization for Tennis Elbow

NCT05325242
View directory record Official record
Conditions
Lateral Epicondylitis, Unspecified Elbow
Interventions
Embozene particles
Device
Lead sponsor
Siddharth Padia, MD
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma

NCT00003897
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
gp100 antigen, sargramostim
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 23, 2026, 4:19 AM EDT
Recruiting Phase 1 Interventional

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

NCT06508463
View directory record Official record
Conditions
Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Relapsed Anaplastic Large Cell Lymphoma, Relapsed Mycosis Fungoides
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Single Photon Emission Computed Tomography, Cemiplimab, Ruxolitinib
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)

NCT00757367
View directory record Official record
Conditions
Healthy Subjects
Interventions
TI Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer

NCT01494155
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Capecitabine, Hydroxychloroquine, Proton or Photon Radiation Therapy
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population

NCT02661490
View directory record Official record
Conditions
Norovirus
Interventions
Norovirus GI.1/GII.4 Bivalent VLP Vaccine, 0.9% sodium chloride (saline)
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor

NCT00102596
View directory record Official record
Conditions
Essential Tremor
Interventions
1-Octanol
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Oct 23, 2026, 4:19 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor

NCT04954664
View directory record Official record
Conditions
Dental Implant, Bone Loss
Interventions
Allograft particles hydrated with rhPDGF, Allograft particles hydrated in a conventional way with saline.
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 23, 2026, 4:19 AM EDT
Active, not recruiting Phase 1 Interventional

IBRX-042 In Participants With HPV-Associated Tumors

NCT05976828
View directory record Official record
Conditions
HPV-Related Carcinoma
Interventions
IBRX-042
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
2
States / cities
El Segundo, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Particle Size Project

NCT05091801
View directory record Official record
Conditions
Test if Increased Chewing Will Increased Microbiota SCFA Production
Interventions
Intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

NCT02788045
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, Ad26.Mos4.HIV, Clade C gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Phase 1 Interventional

Trial of PalloV-CC in Colon Cancer

NCT03827967
View directory record Official record
Conditions
Colon Cancer
Interventions
PalloV-CC
Biological
Lead sponsor
George E. Peoples
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 23, 2026, 4:19 AM EDT
Active, not recruiting Not applicable Interventional

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

NCT02603341
View directory record Official record
Conditions
Breast Cancer
Interventions
Photon, Proton
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
1,238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2036
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 23, 2026, 4:19 AM EDT
Not listed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)

NCT00262067
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Bevacizumab, Placebo, Chemotherapy
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
5
States / cities
Fullerton, California • Santa Barbara, California • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Norovirus Bivalent-Vaccine Efficacy Study

NCT01609257
View directory record Official record
Conditions
Prevention From Norovirus Infection
Interventions
Norovirus Bivalent Vaccine, Saline Comparator
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
5
States / cities
Atlanta, Georgia • Baltimore, Maryland • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cardiovascular Assessment of the Effects of Tobacco and Nicotine Delivery Products

NCT01964807
View directory record Official record
Conditions
Adverse Effect of Other Agents Primarily Affecting the Cardiovascular System, Initial Encounter
Interventions
Cigarette, NIDA test type with 16.6 mg nicotine, Cigarette, NIDA test type with <0.45 mg nicotine, Electronic cigarette with 18 mg/ml nicotine, Electronic Cigarette with no nicotine, Moist snuff, Sham Smoking, Secondhand cigarette smoke (SHS), Conditioned, filtered air, Sham Moist Snuff
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Oct 23, 2026, 4:19 AM EDT
Active, not recruiting No phase listed Observational

Polyethylene Wear Particle Analysis of TKA

NCT06426641
View directory record Official record
Conditions
Wear of Articular Bearing Surface of Prosthetic Joint, Total Knee Arthroplasty
Interventions
Polyethylene
Device
Lead sponsor
Osaka Metropolitan University
Other
Eligibility
20 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 23, 2026, 4:19 AM EDT
Active, not recruiting Not applicable Interventional

A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer

NCT03561220
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard of Care IMRT (Photon), Standard of Care Proton Therapy, Proton Arm 1: Standard Proton Therapy, Proton Arm 2: Hypofractionated Proton Therapy
Radiation
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 85 Years · Male only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Radiesse® Dermal Filler for Hand Treatment

NCT01832090
View directory record Official record
Conditions
Aging Hands
Interventions
Radiesse® Injectable Dermal Filler
Device
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
6
States / cities
San Diego, California • Vista, California • Garden City, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 23, 2026, 4:19 AM EDT
Not listed Not applicable Interventional

An Extension Study MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue

NCT04240639
View directory record Official record
Conditions
Neoplasms of the Prostate
Interventions
AuroShell particle infusion
Device
Lead sponsor
Nanospectra Biosciences, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers

NCT03356561
View directory record Official record
Conditions
Healthy
Interventions
Ad26.ZIKV.001 5*10^10 vp, Ad26.ZIKV.001 1*10^11 vp, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Lenexa, Kansas • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 23, 2026, 4:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

NCT00438880
View directory record Official record
Conditions
Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Agatolimod Sodium, Indium In-111 Ibritumomab Tiuxetan, Laboratory Biomarker Analysis, Radionuclide Imaging, Rituximab, Single Photon Emission Computed Tomography, Yttrium Y-90 Ibritumomab Tiuxetan
Drug · Radiation · Other + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
2
States / cities
Iowa City, Iowa • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 23, 2026, 4:19 AM EDT